BNTC
Benitec Biopharma Inc. Common StockstockNASDAQ
benitec biopharma is using patented 'gene-silencing' technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and 'turns off' specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 9.09 | 2026-11-12 | -9.13% | 4.000 |
| 1M | 8.36 | 2026-10-19 | -1.20% | 1.985 |
| 3M | 13.38 | 2026-08-19 | -38.27% | 1.755 |
| 6M | 10.72 | 2026-05-19 | -22.95% | 1.434 |
| 1Y | 13.10 | 2025-11-19 | -36.95% | 1.617 |
| 2Y | 9.88 | 2024-11-19 | -16.40% | — |
| 5Y | 54.40 | 2021-11-19 | -84.82% | 0.535 |
Benitec Biopharma Inc. Common Stock (NASDAQ:BNTC) stock price today is $8.26, and today's volume is 128,832. BNTC is up 1.350% today. The 30 day average volume is 183,257. BNTC market cap is $298.34M with 36.12M shares outstanding.
